Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,001 to 2,020 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience. | Mediterr J Hematol Infect Dis | 2019 | 30858955 | PubTator, text mining | PubMed |
| CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1. | Blood Cancer J | 2019 | 30850577 | PubTator, text mining | PubMed |
| More than a fusion gene: the RUNX1-RUNX1T1 AML. | Blood | 2019 | 30846508 | PubTator, text mining | PubMed |
| Developmental origins and emerging therapeutic opportunities for childhood cancer. | Nat Med | 2019 | 30842674 | PubTator, text mining | PubMed |
| Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia. | Cancers (Basel) | 2019 | 30841639 | PubTator, text mining | PubMed |
| Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms. | PLoS One | 2019 | 30840646 | PubTator, text mining | PubMed |
| [Co-occurrence of t(8;21)(q22;q22) and t(9;22)(q34;q11) in a case with chronic myelogenous leukemia]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2019 | 30835358 | PubTator, text mining | PubMed |
| [Therapeutic effect of combined use of interferon alpha-1b, interleukin-2 and thalidomide on reversing minimal residual disease in acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2019 | 30831625 | PubTator, text mining | PubMed |
| Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. | Cell | 2019 | 30827681 | PubTator, text mining | PubMed |
| Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway. | Mol Ther Nucleic Acids | 2019 | 30825668 | PubTator, text mining | PubMed |
| A critical role of epigenetic inactivation of miR-9 in EVI1high pediatric AML. | Mol Cancer | 2019 | 30813931 | PubTator, text mining | PubMed |
| Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. | Cancers (Basel) | 2019 | 30813354 | PubTator, text mining | PubMed |
| The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in De Novo Pediatric Acute Leukemias. | Ann Lab Med | 2019 | 30809981 | PubTator, text mining | PubMed |
| Genotoxic and Epigenotoxic Alterations in the Lung and Liver of Mice Induced by Acrylamide: A 28 Day Drinking Water Study. | Chem Res Toxicol | 2019 | 30807115 | PubTator, text mining | PubMed |
| The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes. | Nucleic Acids Res | 2019 | 30805632 | PubTator, text mining | PubMed |
| Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? | Cancers (Basel) | 2019 | 30795628 | PubTator, text mining | PubMed |
| RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells via KLF4-mediated transactivation of P57. | Haematologica | 2019 | 30792202 | PubTator, text mining | PubMed |
| Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. | Front Pharmacol | 2019 | 30761005 | PubTator, text mining | PubMed |
| Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. | Int J Mol Sci | 2019 | 30759825 | PubTator, text mining | PubMed |
| Different prognostic effects of core-binding factor positive AML with Korean AML registry data. | Ann Hematol | 2019 | 30758645 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=101